Intercept Pharmaceuticals announced two abstracts on obeticholic acid will be presented at the NASH-TAG Conference 2023. The conference will be held from January 5 – 7, 2023, in Park City, Utah. "We are looking forward to joining clinicians, researchers and industry peers in-person this year at NASH-TAG 2023 to share additional data from the second interim analysis of our pivotal Phase 3 REGENERATE study," said M. Michelle Berrey, M.D., MPH, President of R&D and Chief Medical Officer of Intercept. "These data demonstrate the robust antifibrotic effect of OCA, as well as its favorable long-term safety profile, and ultimately reaffirm our belief that OCA can be an important treatment for people living with fibrosis due to NASH."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ICPT:
- Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023
- Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH
- Intercept resubmits NDA for obeticholic acid in liver fibrosis due to NASH
- Trial success is rocketing this NASH stock higher and sinking these peers
- RBC Capital says positive Madrigal data further marginalizes OCA NASH prospects
